Maria A Rocca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8310135/publications.pdf

Version: 2024-02-01

589 papers 33,276 citations

92 h-index 9605 147 g-index

602 all docs 602 docs citations

times ranked

602

20396 citing authors

#	Article	IF	CITATIONS
1	Multiple sclerosis. Nature Reviews Disease Primers, 2018, 4, 43.	18.1	767
2	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	4.9	679
3	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511.	6.3	551
4	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurology, The, 2015, 14, 302-317.	4.9	437
5	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€"establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	4.9	422
6	Cognition in multiple sclerosis. Neurology, 2018, 90, 278-288.	1.5	384
7	Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Annals of Neurology, 1998, 43, 809-814.	2.8	356
8	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2012, 11, 349-360.	4.9	356
9	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	4.9	354
10	Functional Magnetic Resonance Imaging Correlates of Fatigue in Multiple Sclerosis. NeuroImage, 2002, 15, 559-567.	2.1	349
11	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. New England Journal of Medicine, 2012, 366, 1000-1009.	13.9	329
12	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	3.7	303
13	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	4.9	302
14	MRI in multiple sclerosis: current status and future prospects. Lancet Neurology, The, 2008, 7, 615-625.	4.9	295
15	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	2.8	295
16	Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology, 2010, 74, 1252-1259.	1.5	292
17	Brain Gray Matter Changes in Migraine Patients With T2-Visible Lesions. Stroke, 2006, 37, 1765-1770.	1.0	291
18	Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Annals of Neurology, 2012, 72, 610-624.	2.8	277

#	Article	IF	CITATIONS
19	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes― Neurology, 2001, 57, 731-733.	1.5	274
20	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	3.7	269
21	Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1082-1091.	0.9	267
22	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 371, 2085-2092.	6.3	265
23	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology, 2011, 76, 418-424.	1.5	259
24	Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology, 2008, 70, 1107-1112.	1.5	258
25	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology, 1998, 50, 1601-1608.	1.5	253
26	A randomised, double blind, placebo controlled trial with vitamin D ₃ as an add on treatment to interferon \hat{I}^2 -1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 565-571.	0.9	242
27	MR Imaging of Multiple Sclerosis. Radiology, 2011, 259, 659-681.	3.6	238
28	Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurology, The, 2005, 4, 618-626.	4.9	235
29	Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis. Neurolmage, 2010, 50, 446-455.	2.1	234
30	Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Annals of Neurology, 2002, 51, 330-339.	2.8	224
31	A Quantitative Study of Water Diffusion in Multiple Sclerosis Lesions and Normal-Appearing White Matter Using Echo-Planar Imaging. Archives of Neurology, 2000, 57, 1017.	4.9	203
32	Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology, 2000, 54, 1139-1144.	1.5	193
33	A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neurolmage, 2008, 42, 315-322.	2.1	189
34	Brain MRI atrophy quantification in MS. Neurology, 2017, 88, 403-413.	1.5	188
35	Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 116-127.	1.4	186
36	Assessment of system dysfunction in the brain through MRI-based connectomics. Lancet Neurology, The, 2013, 12, 1189-1199.	4.9	184

#	Article	IF	CITATIONS
37	A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neurolmage, 2005, 26, 258-265.	2.1	182
38	Multiple Sclerosis: Effects of Cognitive Rehabilitation on Structural and Functional MR Imaging Measures—An Explorative Study. Radiology, 2012, 262, 932-940.	3.6	176
39	Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology, 2013, 81, 1759-1767.	1.5	174
40	Correlations between Structural CNS Damage and Functional MRI Changes in Primary Progressive MS. Neurolmage, 2002, 15, 537-546.	2.1	173
41	MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devicâ \in ^{MS} neuromyelitis optica. Neurology, 1999, 53, 1705-1705.	1.5	172
42	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology, 2010, 75, 2121-2128.	1.5	166
43	Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology, 2012, 79, 1449-1457.	1.5	164
44	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2019, 18, 198-210.	4.9	163
45	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. Neurolmage, 2019, 184, 901-915.	2.1	163
46	Intracortical lesions. Neurology, 2010, 75, 1988-1994.	1.5	159
47	Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology, 2014, 82, 1776-1783.	1.5	156
48	A 3â€year magnetic resonance imaging study of cortical lesions in relapseâ€onset multiple sclerosis. Annals of Neurology, 2010, 67, 376-383.	2.8	153
49	Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Human Brain Mapping, 2007, 28, 1430-1438.	1.9	152
50	Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis. Annals of Neurology, 1998, 43, 332-339.	2.8	150
51	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
52	Brain reserve and cognitive reserve in multiple sclerosis. Neurology, 2013, 80, 2186-2193.	1.5	149
53	Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology, 2002, 58, 866-872.	1.5	147
54	Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. NeuroImage, 2012, 61, 1484-1494.	2.1	145

#	Article	IF	CITATIONS
55	The organization of intrinsic brain activity differs between genders: A restingâ€state fMRI study in a large cohort of young healthy subjects. Human Brain Mapping, 2013, 34, 1330-1343.	1.9	144
56	Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications. Brain, 2001, 124, 1803-1812.	3.7	143
57	Thalamic Damage and Long-term Progression of Disability in Multiple Sclerosis. Radiology, 2010, 257, 463-469.	3.6	143
58	Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neurolmage, 2003, 18, 847-855.	2.1	138
59	A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. Neurology, 2000, 54, 207-207.	1.5	130
60	Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology, 2000, 55, 882-884.	1.5	129
61	A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology, 2011, 76, 2096-2102.	1.5	129
62	Neuroplasticity and functional recovery in multiple sclerosis. Nature Reviews Neurology, 2012, 8, 635-646.	4.9	128
63	Cortical lesions in primary progressive multiple sclerosis. Neurology, 2009, 72, 1330-1336.	1.5	124
64	The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology, 2010, 31, 1769-1777.	1.2	124
65	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. Neurolmage, 2005, 26, 822-828.	2.1	123
66	Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disorders, 2011, 13, 414-424.	1.1	122
67	Impaired functional integration in multiple sclerosis: a graph theory study. Brain Structure and Function, 2016, 221, 115-131.	1.2	122
68	High prevalence of restless legs syndrome in multiple sclerosis. European Journal of Neurology, 2007, 14, 534-539.	1.7	121
69	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon \hat{I}^21a . Annals of Neurology, 2003, 53, 718-724.	2.8	120
70	MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. Journal of Neurology, 2005, 252, v16-v24.	1.8	120
71	Magnetic Resonance Techniques in Multiple Sclerosis. Archives of Neurology, 2011, 68, 1514.	4.9	120
72	Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology, 2004, 62, 476-478.	1.5	118

#	Article	IF	Citations
73	Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Multiple Sclerosis Journal, 2008, 14, 86-93.	1.4	117
74	A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 53-55.	0.9	117
75	Structural and functional MRI correlates of Stroop control in benign MS. Human Brain Mapping, 2009, 30, 276-290.	1.9	117
76	Altered functional and structural connectivities in patients with MS. Neurology, 2007, 69, 2136-2145.	1.5	116
77	Voxel-based analysis derived from fractional anisotropy images of white matter volume changes with aging. Neurolmage, 2008, 41, 657-667.	2.1	113
78	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. American Journal of Neuroradiology, 2005, 26, 341-6.	1.2	113
79	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurology, The, 2006, 5, 221-227.	4.9	112
80	Multi-branch convolutional neural network for multiple sclerosis lesion segmentation. NeuroImage, 2019, 196, 1-15.	2.1	111
81	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
82	Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology, 2012, 78, 969-975.	1.5	109
83	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nature Reviews Neurology, 2015, 11, 676-686.	4.9	109
84	Cortical Abnormalities in Patients with Migraine: A Surface-based Analysis. Radiology, 2013, 268, 170-180.	3.6	105
85	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurology, The, 2015, 14, 443-454.	4.9	105
86	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. Multiple Sclerosis Journal, 2018, 24, 459-471.	1.4	105
87	Selective decreased grey matter volume of the pain-matrix network in cluster headache. Cephalalgia, 2012, 32, 109-115.	1.8	101
88	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	0.9	101
89	Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. Neurology, 2005, 64, 631-635.	1.5	99
90	Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping, 2009, 30, 2656-2666.	1.9	99

#	Article	IF	Citations
91	Structural <scp>MRI</scp> correlates of cognitive impairment in patients with multiple sclerosis. Human Brain Mapping, 2016, 37, 1627-1644.	1.9	99
92	Assessing response to interferon- \hat{l}^2 in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
93	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
94	Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 192-201.	1.4	97
95	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Human Brain Mapping, 2004, 21, 108-117.	1.9	96
96	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. Journal of Neurology, 2013, 260, 2458-2471.	1.8	96
97	Functional MRI in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 36S-41S.	1.0	95
98	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis Journal, 2014, 20, 72-80.	1.4	95
99	Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2010, 31, 515-525.	1.9	93
100	Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Human Brain Mapping, 2011, 32, 1535-1543.	1.9	92
101	Meeting Review: The management of multiple sclerosis in children: a European view. Multiple Sclerosis Journal, 2010, 16, 1258-1267.	1.4	91
102	The hippocampus in multiple sclerosis. Lancet Neurology, The, 2018, 17, 918-926.	4.9	90
103	The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurology, The, 2003, 2, 337-346.	4.9	88
104	A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. Neurolmage, 2003, 19, 1770-1777.	2.1	88
105	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88
106	Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology, 2010, 75, 912-917.	1.5	87
107	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 1074-1083.	1.4	87
108	Regional but Not Global Brain Damage Contributes to Fatigue in Multiple Sclerosis. Radiology, 2014, 273, 511-520.	3.6	87

#	Article	IF	Citations
109	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414.	4.5	86
110	MRI assessment of iron deposition in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2011, 34, 13-21.	1.9	84
111	fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNβ-1a injection. Human Brain Mapping, 2007, 28, 373-382.	1.9	83
112	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology, 1998, 50, 1289-1293.	1.5	81
113	Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. Human Brain Mapping, 2008, 29, 562-573.	1.9	81
114	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain, 2021, 144, 1296-1311.	3.7	81
115	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1344-1350.	0.9	80
116	Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study. American Journal of Neuroradiology, 2017, 38, 18-24.	1.2	80
117	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. Annals of Neurology, 2020, 88, 93-105.	2.8	79
118	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis Journal, 2005, 11, 441-446.	1.4	78
119	Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics, 2007, 4, 401-413.	2.1	78
120	Cardiovascular disease and brain health: Focus on white matter hyperintensities. IJC Heart and Vasculature, 2018, 19, 63-69.	0.6	78
121	Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. Brain, 2022, 145, 2785-2795.	3.7	78
122	Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. Neurology, 1997, 49, 371-377.	1.5	77
123	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Multiple Sclerosis Journal, 2018, 24, 214-221.	1.4	77
124	Voxelwise Assessment of the Regional Distribution of Damage in the Brains of Patients with Multiple Sclerosis and Fatigue. American Journal of Neuroradiology, 2011, 32, 874-879.	1.2	76
125	Structural brain MRI abnormalities in pediatric patients with migraine. Journal of Neurology, 2014, 261, 350-357.	1.8	76
126	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multiâ€centre fMRI study. European Journal of Neurology, 2008, 15, 113-122.	1.7	75

#	Article	IF	Citations
127	Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain, 2019, 142, 633-646.	3.7	7 5
128	The Brain Functional Networks Associated to Human and Animal Suffering Differ among Omnivores, Vegetarians and Vegans. PLoS ONE, 2010, 5, e10847.	1.1	75
129	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology, 2009, 73, 1842-1848.	1.5	74
130	Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. Brain Structure and Function, 2015, 220, 435-444.	1.2	74
131	Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 643-4.	0.9	74
132	Magnetization Transfer Magnetic Resonance Imaging in the Assessment of Neurological Diseases. Journal of Neuroimaging, 2004, 14, 303-313.	1.0	73
133	Normal-appearing white and grey matter damage in MS. Journal of Neurology, 2007, 254, 513-518.	1.8	73
134	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. Human Brain Mapping, 2014, 35, 5799-5814.	1.9	73
135	Cognitive rehabilitation correlates with the functional connectivity of the anterior cingulate cortex in patients with multiple sclerosis. Brain Imaging and Behavior, 2014, 8, 387-393.	1.1	73
136	Functional and Structural Connectivity of the Motor Network in Pediatric and Adult-Onset Relapsing-Remitting Multiple Sclerosis. Radiology, 2010, 254, 541-550.	3.6	72
137	Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurology, 2015, 15, 174.	0.8	72
138	Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. Magnetic Resonance Imaging, 1999, 17, 1521-1523.	1.0	69
139	Selective Diffusion Changes of The Visual Pathways in Patients with Migraine: A 3-T Tractography Study. Cephalalgia, 2008, 28, 1061-1068.	1.8	69
140	Connectivityâ€based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. Human Brain Mapping, 2015, 36, 2809-2825.	1.9	69
141	Motor Learning in Healthy Humans Is Associated to Gray Matter Changes: A Tensor-Based Morphometry Study. PLoS ONE, 2010, 5, e10198.	1.1	68
142	Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 821-7.	1.2	68
143	Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brain. NeuroImage, 2003, 19, 826-836.	2.1	67
144	Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 137-141.	0.3	67

#	Article	IF	CITATIONS
145	Identifying Progression in Multiple Sclerosis: New Perspectives. Annals of Neurology, 2020, 88, 438-452.	2.8	67
146	Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 686-694.	1.4	66
147	Brain and cord imaging features in neuromyelitis optica spectrum disorders. Annals of Neurology, 2019, 85, 371-384.	2.8	66
148	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 2008, 255, 683-691.	1.8	65
149	Phase III doseâ€comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 2011, 69, 75-82.	2.8	65
150	Intrinsic Damage to the Major White Matter Tracts in Patients with Different Clinical Phenotypes of Multiple Sclerosis: A Voxelwise Diffusion-Tensor MR Study. Radiology, 2011, 260, 541-550.	3.6	65
151	Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 524-529.	1.1	65
152	Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?. Human Brain Mapping, 2009, 30, 2844-2851.	1.9	64
153	Thalamic Damage Predicts the Evolution of Primary-Progressive Multiple Sclerosis at 5 Years. American Journal of Neuroradiology, 2011, 32, 1016-1020.	1.2	64
154	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. Journal of Neurology, 2013, 260, 2016-2022.	1.8	63
155	Imaging resting state brain function in multiple sclerosis. Journal of Neurology, 2013, 260, 1709-1713.	1.8	62
156	Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 1710-6.	1.2	62
157	Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 785-788.	0.9	61
158	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. European Journal of Neurology, 2006, 13, 313-325.	1.7	61
159	Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. Journal of the Neurological Sciences, 2002, 194, 71-74.	0.3	60
160	European Study on Intravenous Immunoglobulin in Multiple Sclerosis. Archives of Neurology, 2004, 61, 1409.	4.9	60
161	Conventional MRI in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 3S-9S.	1.0	60
162	Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis. Journal of the Neurological Sciences, 1998, 158, 148-153.	0.3	59

#	Article	IF	Citations
163	Cortical reorganisation in patients with MS. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1087-1089.	0.9	59
164	A functional MRI study of movement-associated cortical changes in patients with Devic's neuromyelitis optica. NeuroImage, 2004, 21, 1061-1068.	2.1	59
165	A functional MRI study of cortical activations associated with object manipulation in patients with MS. Neurolmage, 2004, 21, 1147-1154.	2.1	59
166	Cognitive learning is associated with gray matter changes in healthy human individuals: A tensor-based morphometry study. Neurolmage, 2009, 48, 585-589.	2.1	59
167	Abnormalities of Resting State Functional Connectivity Are Related to Sustained Attention Deficits in MS. PLoS ONE, 2012, 7, e42862.	1.1	59
168	Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1633-1640.	1.4	59
169	Magnetization transfer imaging of patients with definite MS and negative conventional MRI. Neurology, 1999, 52, 845-845.	1.5	59
170	MRI quantification of gray and white matter damage in patients with early–onset multiple sclerosis. Journal of Neurology, 2006, 253, 903-907.	1.8	58
171	Magnetic resonance outcome measures in multiple sclerosis trials. Current Opinion in Neurology, 2014, 27, 290-299.	1.8	58
172	Hippocampalâ€ <scp>DMN</scp> disconnectivity in <scp>MS</scp> is related to <scp>WM</scp> lesions and depression. Human Brain Mapping, 2015, 36, 5051-5063.	1.9	58
173	MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 537-542.	0.9	58
174	Carotid atherosclerosis, silent ischemic brain damage and brain atrophy: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 223, 681-687.	0.8	58
175	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. Frontiers in Neurology, 2017, 8, 433.	1.1	58
176	Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 39-44.	1.4	57
177	A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. Journal of Neurology, 2002, 249, 535-537.	1.8	56
178	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions. Journal of Neurology, 2003, 250, 456-460.	1.8	56
179	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	1.4	56
180	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. Neurology, 2014, 82, 1314-1321.	1.5	56

#	Article	IF	Citations
181	T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 678-686.	1.4	55
182	Central nervous system dysregulation extends beyond the pain-matrix network in cluster headache. Cephalalgia, 2010, 30, 1383-1391.	1.8	55
183	Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: a diffusion tensor MRI study. Multiple Sclerosis Journal, 2013, 19, 1610-1617.	1.4	55
184	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. Multiple Sclerosis Journal, 2016, 22, 1144-1153.	1.4	55
185	Pyramidal tract lesions and movement-associated cortical recruitment in patients with MS. Neurolmage, 2004, 23, 141-147.	2.1	54
186	Patients with migraine do not have MRI-visible cortical lesions. Journal of Neurology, 2012, 259, 2695-2698.	1.8	54
187	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1183-1195.	1.4	54
188	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 476-488.	1.4	54
189	A magnetization transfer imaging study of the brain in patients with migraine. Neurology, 2000, 54, 507-507.	1.5	53
190	Evidence for Cortical Functional Changes in Patients With Migraine and White Matter Abnormalities on Conventional and Diffusion Tensor Magnetic Resonance Imaging. Stroke, 2003, 34, 665-670.	1.0	53
191	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	1.4	53
192	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Multiple Sclerosis Journal, 2007, 13, 502-508.	1.4	53
193	Evidence for retrochiasmatic tissue loss in Leber's hereditary optic neuropathy. Human Brain Mapping, 2010, 31, 1900-1906.	1.9	53
194	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013, 80, 234-241.	1.5	53
195	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. Multiple Sclerosis Journal, 2017, 23, 1194-1203.	1.4	53
196	A Preliminary Diffusion Tensor and Magnetization Transfer Magnetic Resonance Imaging Study of Early-Onset Multiple Sclerosis. Archives of Neurology, 2004, 61, 366.	4.9	52
197	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Experimental Brain Research, 2008, 187, 25-31.	0.7	52
198	MR Imaging of Gray Matter Involvement in Multiple Sclerosis: Implications for Understanding Disease Pathophysiology and Monitoring Treatment Efficacy. American Journal of Neuroradiology, 2010, 31, 1171-1177.	1.2	52

#	Article	IF	CITATIONS
199	Mapping regional grey and white matter atrophy in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1027-1037.	1.4	52
200	A diffusion tensor magnetic resonance imaging study of brain tissue from patients with migraine. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 501-503.	0.9	51
201	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. Human Brain Mapping, 2009, 30, 2412-2425.	1.9	51
202	Evidence for acute neurotoxicity after chemotherapy. Annals of Neurology, 2010, 68, 806-815.	2.8	51
203	Preserved brain adaptive properties in patients with benign multiple sclerosis. Neurology, 2010, 74, 142-149.	1.5	51
204	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain, 2017, 140, 2814-2819.	3.7	51
205	Brain mapping in multiple sclerosis: Lessons learned about the human brain. NeuroImage, 2019, 190, 32-45.	2.1	51
206	Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. Journal of the Neurological Sciences, 1998, 159, 162-165.	0.3	50
207	Evidence for enhanced functional activity of cervical cord in relapsing multiple sclerosis. Magnetic Resonance in Medicine, 2008, 59, 1035-1042.	1.9	50
208	The topographical distribution of tissue injury in benign MS: A 3T multiparametric MRI study. Neurolmage, 2008, 39, 1499-1509.	2.1	49
209	Reproducibility of fMRI in the clinical setting: Implications for trial designs. NeuroImage, 2008, 42, 603-610.	2.1	49
210	Gray matter volume modifications in migraine. Neurology, 2018, 91, e280-e292.	1.5	49
211	The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. Journal of Neurology, 2021, 268, 1598-1607.	1.8	49
212	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. Journal of the Neurological Sciences, 1999, 171, 135-144.	0.3	48
213	MRI features of benign multiple sclerosis. Neurology, 2009, 72, 1693-1701.	1.5	48
214	Functional MR Imaging in Multiple Sclerosis. Neuroimaging Clinics of North America, 2009, 19, 59-70.	0.5	48
215	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1864-1874.	1.4	48
216	The role of the cerebellum in multiple sclerosis—150 years after Charcot. Neuroscience and Biobehavioral Reviews, 2018, 89, 85-98.	2.9	48

#	Article	IF	CITATIONS
217	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. Journal of the Neurological Sciences, 2003, 216, 169-177.	0.3	47
218	Cortical lesions in children with multiple sclerosis. Neurology, 2011, 76, 910-913.	1.5	47
219	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	1.4	47
220	Ultra-high-field MR imaging in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 60-66.	0.9	47
221	Relationship between Damage to the Cerebellar Peduncles and Clinical Disability in Multiple Sclerosis. Radiology, 2014, 271, 822-830.	3.6	47
222	The effect of action observation/execution on mirror neuron system recruitment: an fMRI study in healthy individuals. Brain Imaging and Behavior, 2017, 11, 565-576.	1.1	47
223	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology, 2018, 288, 554-564.	3. 6	47
224	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neurolmage: Clinical, 2018, 19, 466-475.	1.4	47
225	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	1.8	47
226	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	0.9	46
227	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nature Reviews Neurology, 2021, 17, 173-184.	4.9	46
228	Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. Journal of Neurology, 2022, 269, 1316-1334.	1.8	46
229	Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS. Neurology, 2007, 68, 939-944.	1.5	45
230	MRI and cognition in multiple sclerosis. Neurological Sciences, 2010, 31, 231-234.	0.9	45
231	Functional magnetic resonance imaging correlates of cognitive performance in patients with a clinically isolated syndrome suggestive of multiple sclerosis at presentation: an activation and connectivity study. Multiple Sclerosis Journal, 2012, 18, 153-163.	1.4	45
232	Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Current Opinion in Neurology, 2003, 16, 275-282.	1.8	44
233	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
234	The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis. Neurology, 1997, 49, 274-276.	1.5	43

#	Article	IF	CITATIONS
235	A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Human Brain Mapping, 2009, 30, 3009-3019.	1.9	43
236	Neuropsychological rehabilitation in adult multiple sclerosis. Neurological Sciences, 2010, 31, 271-274.	0.9	43
237	Interferon \hat{l}^2 -1b and glatiramer acetate effects on permanent black hole evolution. Neurology, 2011, 76, 1222-1228.	1.5	43
238	Cord damage elicits brain functional reorganization after a single episode of myelitis. Neurology, 2003, 61, 1078-1085.	1.5	42
239	Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 35-41.	0.9	42
240	Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis. Radiology, 2013, 266, 853-861.	3.6	42
241	White matter microstructure abnormalities in pediatric migraine patients. Cephalalgia, 2015, 35, 1278-1286.	1.8	42
242	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.5	42
243	Structural brain abnormalities in patients with vestibular migraine. Journal of Neurology, 2017, 264, 295-303.	1.8	42
244	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. NeuroImage: Clinical, 2019, 24, 102011.	1.4	42
245	MR imaging of Devic?s neuromyelitis optica. Neurological Sciences, 2004, 25, s371-s373.	0.9	41
246	Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue. Multiple Sclerosis Journal, 2016, 22, 1665-1675.	1.4	41
247	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	41
248	Diffusion tensor magnetic resonance imaging at 3.0 tesla shows subtle cerebral grey matter abnormalities in patients with migraine. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 686-689.	0.9	40
249	Present and future of fMRI in multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 27-31.	1.4	40
250	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. Human Brain Mapping, 2014, 35, 4180-4192.	1.9	40
251	Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. Multiple Sclerosis Journal, 2016, 22, 901-909.	1.4	40
252	Structural connectivityâ€defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. Human Brain Mapping, 2017, 38, 6005-6018.	1.9	40

#	Article	lF	Citations
253	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. Radiology, 2018, 288, 234-244.	3.6	40
254	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	1.5	40
255	Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study. Multiple Sclerosis Journal, 2019, 25, 372-381.	1.4	40
256	MR imaging assessment of brain and cervical cord damage in patients with neuroborreliosis. American Journal of Neuroradiology, 2006, 27, 892-4.	1.2	39
257	Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis. NeuroImage, 2009, 45, 500-511.	2.1	38
258	Structural and functional magnetic resonance imaging correlates of motor network dysfunction in primary progressive multiple sclerosis. European Journal of Neuroscience, 2010, 31, 1273-1280.	1.2	38
259	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 26-30.	0.9	38
260	Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 418-426.	1.4	38
261	Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes—A 2-year MR Imaging Study. Radiology, 2016, 278, 841-853.	3.6	38
262	Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex. Brain, 2019, 142, 1921-1937.	3.7	38
263	Magnetization-transfer histogram analysis of the cervical cord in patients with multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 1803-8.	1.2	38
264	Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. Journal of Neurology, 1999, 246, 689-692.	1.8	37
265	An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus. NeuroImage, 2006, 30, 478-484.	2.1	37
266	Spatial Normalization and Regional Assessment of Cord Atrophy: Voxel-Based Analysis of Cervical Cord 3D T1-Weighted Images. American Journal of Neuroradiology, 2012, 33, 2195-2200.	1.2	37
267	Resting-state fMRI functional connectivity: a new perspective to evaluate pain modulation in migraine?. Neurological Sciences, 2015, 36, 41-45.	0.9	37
268	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. Multiple Sclerosis Journal, 2016, 22, 269-278.	1.4	37
269	Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5â€year study. Human Brain Mapping, 2017, 38, 5648-5665.	1.9	37
270	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology, 2019, 93, e1852-e1866.	1.5	37

#	Article	IF	CITATIONS
271	Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases., 2004, 14, 303-13.		37
272	Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. Journal of Neurology, 2013, 260, 327-329.	1.8	36
273	Power estimation for non-standardized multisite studies. Neurolmage, 2016, 134, 281-294.	2.1	36
274	An MR study of tissue damage in the cervical cord of patients with migraine. Journal of the Neurological Sciences, 2001, 183, 43-46.	0.3	34
275	Imaging the optic nerve in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 537-541.	1.4	34
276	Combining Functional and Structural Brain Magnetic Resonance Imaging in Huntington Disease. Journal of Computer Assisted Tomography, 2007, 31, 574-580.	0.5	34
277	Functional MR Imaging Correlates of Neuropsychological Impairment in Primary-Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2010, 31, 1240-1246.	1.2	34
278	Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. Brain, 2020, 143, 2089-2105.	3.7	34
279	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Multiple Sclerosis Journal, 2004, 10, S36-S45.	1.4	33
280	Functional MRI to study brain plasticity in clinical neurology. Neurological Sciences, 2006, 27, s24-s26.	0.9	33
281	A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2007, 28, 1659-1661.	1.2	33
282	Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1552-1559.	1.4	33
283	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. European Journal of Neurology, 2016, 23, 39-44.	1.7	33
284	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 204-216.	1.4	33
285	Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 813-20.	1.2	33
286	Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Current Opinion in Neurology, 2003, 16, 275-282.	1.8	32
287	The "mirror-neuron system―in MS. Neurology, 2008, 70, 255-262.	1.5	32
288	Microstructural MR Imaging Techniques inÂMultiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 313-333.	0.5	32

#	Article	IF	Citations
289	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. Annals of Neurology, 2019, 86, 704-713.	2.8	32
290	Intraobserver and interobserver variability in schemes for estimating volume of brain lesions on MR images in multiple sclerosis. American Journal of Neuroradiology, 1998, 19, 239-44.	1.2	32
291	Differential Cerebellar Functional Interactions during an Interference Task across Multiple Sclerosis Phenotypes. Radiology, 2012, 265, 864-873.	3.6	31
292	Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology, 2016, 86, 2006-2009.	1.5	31
293	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
294	A widespread pattern of cortical activations in patients at presentation with clinically isolated symptoms is associated with evolution to definite multiple sclerosis. American Journal of Neuroradiology, 2005, 26, 1136-9.	1.2	31
295	A magnetic resonance imaging study of the cervical cord of patients with CADASIL. Neurology, 2001, 56, 1392-1394.	1.5	30
296	Evidence of Subtle Gray-Matter Pathologic Changes in Healthy Elderly Individuals With Nonspecific White-Matter Hyperintensities. Archives of Neurology, 2003, 60, 1109.	4.9	30
297	Influence of task complexity during coordinated hand and foot movements in MS patients with and without fatigue. Journal of Neurology, 2009, 256, 470-482.	1.8	30
298	Characterizing Rapid Fluctuations of Resting State Functional Connectivity in Demyelinating, Neurodegenerative, and Psychiatric Conditions: From Static to Time-Varying Analysis. Frontiers in Neuroscience, 2019, 13, 618.	1.4	30
299	Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. European Journal of Neurology, 2020, 27, 2549-2560.	1.7	30
300	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
301	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). BMC Neurology, 2020, 20, 204.	0.8	30
302	Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. Journal of Neurology, 2008, 255, 1378-1383.	1.8	29
303	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Current Opinion in Neurology, 2016, 29, 243-253.	1.8	29
304	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. Human Brain Mapping, 2016, 37, 2293-2304.	1.9	29
305	Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study. Radiology, 2016, 280, 869-879.	3.6	29
306	Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. Magnetic Resonance Imaging, 1999, 17, 979-984.	1.0	28

#	Article	IF	CITATIONS
307	Subcortical Damage and Cortical Functional Changes in Men and Women with Fabry Disease: A Multifaceted MR Study. Radiology, 2006, 241, 492-500.	3 . 6	28
308	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 628-640.	1.4	28
309	MRI in multiple sclerosis: what is changing?. Current Opinion in Neurology, 2018, 31, 386-395.	1.8	28
310	Structural connectivity in multiple sclerosis and modeling of disconnection. Multiple Sclerosis Journal, 2020, 26, 220-232.	1.4	28
311	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. Neurotherapeutics, 2020, 17, 208-217.	2.1	28
312	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. Neurology, 2021, 96, e1561-e1573.	1.5	28
313	Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. American Journal of Neuroradiology, 2000, 21, 133-6.	1.2	28
314	Assessing atrophy of the major white matter fiber bundles of the brain from diffusion tensor MRI data. Magnetic Resonance in Medicine, 2007, 58, 527-534.	1.9	27
315	Patterns of white matter diffusivity abnormalities in Leber's hereditary optic neuropathy: a tract-based spatial statistics study. Journal of Neurology, 2012, 259, 1801-1807.	1.8	27
316	Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis. Human Brain Mapping, 2012, 33, 2072-2080.	1.9	27
317	The role of advanced magnetic resonance imaging techniques in primary progressive MS. Journal of Neurology, 2012, 259, 611-621.	1.8	27
318	Imaging Cortical Damage and Dysfunction in Multiple Sclerosis. JAMA Neurology, 2013, 70, 556.	4. 5	27
319	Functional MRI in investigating cognitive impairment in multiple sclerosis. Acta Neurologica Scandinavica, 2016, 134, 39-46.	1.0	27
320	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. Neurological Sciences, 2016, 37, 1399-1402.	0.9	27
321	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. NeuroImage, 2017, 163, 106-114.	2.1	27
322	Dynamic gray matter volume changes in pediatric multiple sclerosis. Neurology, 2019, 92, e1709-e1723.	1.5	27
323	Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis. Acta Neurologica Scandinavica, 1997, 95, 331-334.	1.0	26
324	Comparative study of mitoxantrone efficacy profile in patients with relapsingâ€"remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1490-1499.	1.4	26

#	Article	IF	Citations
325	FMRI correlates of execution and observation of foot movements in left-handers. Journal of the Neurological Sciences, 2010, 288, 34-41.	0.3	26
326	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. Multiple Sclerosis Journal, 2017, 23, 577-587.	1.4	26
327	Functional and structural plasticity following action observation training in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1472-1487.	1.4	26
328	Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 134-138.	1.4	26
329	A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads. Journal of the Neurological Sciences, 1998, 158, 203-208.	0.3	25
330	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. European Journal of Neuroscience, 2011, 33, 1256-1263.	1.2	25
331	Future MRI tools in multiple sclerosis. Journal of the Neurological Sciences, 2013, 331, 14-18.	0.3	25
332	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 1471-1477.	1.4	25
333	Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis. Radiology, 2020, 296, 605-615.	3.6	25
334	Multiparametric MRI in a patient with adult-onset leukoencephalopathy with vanishing white matter. Neurology, 2004, 62, 323-326.	1.5	24
335	Extra-Visual Functional and Structural Connection Abnormalities in Leber's Hereditary Optic Neuropathy. PLoS ONE, 2011, 6, e17081.	1.1	24
336	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 702-707.	1.4	24
337	In vivo evidence of hippocampal dentate gyrus expansion in multiple sclerosis. Human Brain Mapping, 2015, 36, 4702-4713.	1.9	24
338	Two-year dynamic functional network connectivity in clinically isolated syndrome. Multiple Sclerosis Journal, 2020, 26, 645-658.	1.4	24
339	Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 790-792.	0.9	24
340	The level of spinal cord involvement influences the pattern of movement-associated cortical recruitment in patients with isolated myelitis. NeuroImage, 2006, 30, 879-884.	2.1	23
341	Tactileâ€associated fMRI recruitment of the cervical cord in healthy subjects. Human Brain Mapping, 2009, 30, 340-345.	1.9	23
342	Brain macro- and microscopic damage in patients with paediatric MS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1357-1362.	0.9	23

#	Article	IF	CITATIONS
343	MRI Predicts Efficacy of Constraint-Induced Movement Therapy in Children With Brain Injury. Neurotherapeutics, 2013, 10, 511-519.	2.1	23
344	Role of artificial intelligence in MS clinical practice. NeuroImage: Clinical, 2022, 35, 103065.	1.4	23
345	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 789-794.	1.4	22
346	Multiple sclerosis imaging: recent advances. Journal of Neurology, 2013, 260, 929-935.	1.8	22
347	Elevated body temperature is linked to fatigue in an Italian sample of relapsing–remitting multiple sclerosis patients. Journal of Neurology, 2015, 262, 2440-2442.	1.8	22
348	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1621-1625.	1.4	22
349	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. Multiple Sclerosis Journal, 2015, 21, 956-959.	1.4	21
350	Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients. Scientific Reports, 2017, 7, 10559.	1.6	21
351	Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. American Journal of Neuroradiology, 1999, 20, 133-7.	1.2	21
352	MRI aspects of the ?inflammatory phase? of multiple sclerosis. Neurological Sciences, 2003, 24, s275-s278.	0.9	20
353	A diffusion tensor MRI study of basal ganglia from patients with ADEM. Journal of the Neurological Sciences, 2003, 206, 27-30.	0.3	20
354	A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. Multiple Sclerosis Journal, 2007, 13, 265-268.	1.4	20
355	Incorporating Domain Knowledge Into the Fuzzy Connectedness Framework: Application to Brain Lesion Volume Estimation in Multiple Sclerosis. IEEE Transactions on Medical Imaging, 2007, 26, 1670-1680.	5.4	20
356	Influence of body segment position during in-phase and antiphase hand and foot movements: A kinematic and functional MRI study. Human Brain Mapping, 2007, 28, 218-227.	1.9	20
357	The mirrorâ€neuron system and handedness: A "right†world?. Human Brain Mapping, 2008, 29, 1243-1254.	1.9	20
358	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. Multiple Sclerosis Journal, 2021, 27, 841-854.	1.4	20
359	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. NeuroImage: Clinical, 2021, 29, 102549.	1.4	20
360	Deep Learning on Conventional Magnetic Resonance Imaging Improves the Diagnosis of Multiple Sclerosis Mimics. Investigative Radiology, 2021, 56, 252-260.	3.5	20

#	Article	IF	CITATIONS
361	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. Journal of Magnetic Resonance Imaging, 2008, 28, 559-565.	1.9	19
362	Insights from magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 115-149.	1.0	19
363	A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. Journal of Neurology, 2015, 262, 1622-1628.	1.8	19
364	Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 620-627.	1.4	19
365	Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 675-678.	1.4	19
366	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. Multiple Sclerosis Journal, 2020, 26, 233-244.	1.4	19
367	Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis. Radiologia Medica, 2013, 118, 251-264.	4.7	18
368	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 316-318.	0.9	18
369	Structural and functional brain connectomes in patients with systemic lupus erythematosus. European Journal of Neurology, 2020, 27, 113.	1.7	18
370	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging. Investigative Radiology, 2022, 57, 423-432.	3.5	18
371	Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica. Annals of Neurology, 2022, 92, 173-183.	2.8	18
372	Novel MRI approaches to assess patients with multiple sclerosis. Current Opinion in Neurology, 2010, 23, 212-217.	1.8	17
373	Motor area localization using fMRI-constrained cortical current density reconstruction of movement-related cortical potentials, a comparison with fMRI and TMS mapping. Brain Research, 2010, 1308, 68-78.	1.1	17
374	Overcoming the Clinical–MR Imaging Paradox of Multiple Sclerosis: MR Imaging Data Assessed with a Random Forest Approach. American Journal of Neuroradiology, 2011, 32, 2098-2102.	1.2	17
375	Analysis of "task-positive―and "task-negative―functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis. Experimental Brain Research, 2013, 225, 399-407.	0.7	17
376	Multicenter mapping in the healthy brain. Magnetic Resonance in Medicine, 2014, 71, 1103-1107.	1.9	17
377	Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. Expert Review of Neurotherapeutics, 2019, 19, 835-866.	1.4	17
378	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. Multiple Sclerosis Journal, 2019, 25, 801-810.	1.4	17

#	Article	IF	Citations
379	<i>In vivo</i> gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. Brain, 2021, 144, 186-197.	3.7	17
380	Effect of cognitive reserve on structural and functional MRI measures in healthy subjects: a multiparametric assessment. Journal of Neurology, 2021, 268, 1780-1791.	1.8	17
381	Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. Magnetic Resonance Imaging, 1999, 17, 1105-1110.	1.0	16
382	Validation of 1â€year predictive score of longâ€ŧerm response to interferonâ€Î² in everyday clinical practice multiple sclerosis patients. European Journal of Neurology, 2015, 22, 973-980.	1.7	16
383	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 399-423.	1.0	16
384	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 292-301.	1.4	16
385	MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. Journal of Neurology, 2019, 266, 2848-2858.	1.8	16
386	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1520-1532.	1.4	16
387	Network Damage Predicts Clinical Worsening in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
388	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. Multiple Sclerosis Journal, 2002, 8, 52-58.	1.4	15
389	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Multiple Sclerosis Journal, 2004, 10, S36-S45.	1.4	15
390	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. Multiple Sclerosis Journal, 2009, 15, 465-471.	1.4	15
391	Brain connectivity abnormalities extend beyond the sensorimotor network in peripheral neuropathy. Human Brain Mapping, 2014, 35, 513-526.	1.9	15
392	Functional reorganization is a maladaptive response to injury – YES. Multiple Sclerosis Journal, 2017, 23, 191-193.	1.4	15
393	Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study. Journal of Neurology, 2020, 267, 3508-3517.	1.8	15
394	Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. Multiple Sclerosis Journal, 2010, 16, 325-331.	1.4	14
395	Altered neural mechanisms of cognitive control in patients with primary progressive multiple sclerosis: An effective connectivity study. Human Brain Mapping, 2017, 38, 2580-2588.	1.9	14
396	The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. Neurological Sciences, 2017, 38, 1029-1038.	0.9	14

#	Article	IF	Citations
397	Progression of brain white matter hyperintensities in asymptomatic patients with carotid atherosclerotic plaques and no indication for revascularization. Atherosclerosis, 2019, 287, 171-178.	0.4	14
398	Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2020, 26, 795-805.	1.4	14
399	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. Molecular Psychiatry, 2021, 26, 3634-3645.	4.1	14
400	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. Journal of Neurology, 2020, 268, 2697-2699.	1.8	14
401	What role should spinal cord MRI take in the future of multiple sclerosis surveillance?. Expert Review of Neurotherapeutics, 2020, 20, 783-797.	1.4	14
402	Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. Expert Review of Neurotherapeutics, 2020, 20, 747-769.	1.4	14
403	Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging. Multiple Sclerosis Journal, 2021, 27, 818-826.	1.4	14
404	Dynamic Functional Connectivity in the Main Clinical Phenotypes of Multiple Sclerosis. Brain Connectivity, 2021, 11, 678-690.	0.8	14
405	Clinical correlates of hypothalamic functional changes in migraine patients. Cephalalgia, 2022, 42, 279-290.	1.8	14
406	Imaging Spinal Cord Damage in Multiple Sclerosis. Journal of Neuroimaging, 2005, 15, 297-304.	1.0	13
407	Anton's Syndrome following Callosal Disconnection. Behavioural Neurology, 2007, 18, 183-186.	1.1	13
408	Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective. American Journal of Neuroradiology, 2011, 32, 424-427.	1.2	13
409	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. Multiple Sclerosis Journal, 2017, 23, 1918-1928.	1.4	13
410	A diffusion tensor magnetic resonance imaging study of paediatric patients with severe nonâ€traumatic brain injury. Developmental Medicine and Child Neurology, 2017, 59, 199-206.	1.1	13
411	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. Neurology, 2017, 89, 1265-1273.	1.5	13
412	Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. Radiology, 2020, 297, 154-163.	3.6	13
413	Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study. Multiple Sclerosis Journal, 2021, 27, 380-390.	1.4	13
414	Early Predictors of 9‥ear Disability in Pediatric Multiple Sclerosis. Annals of Neurology, 2021, 89, 1011-1022.	2.8	13

#	Article	IF	Citations
415	Unraveling the substrates of cognitive impairment in multiple sclerosis: A multiparametric structural and functional magnetic resonance imaging study. European Journal of Neurology, 2021, 28, 3749-3759.	1.7	13
416	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 608-619.	1.4	13
417	Imaging spinal cord damage in multiple sclerosis. , 2005, 15, 297-304.		13
418	A comparison of MR imaging with fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR sequences in the assessment of patients with multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 1931-8.	1.2	13
419	MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a) Tj ETQq $1\ 1\ 0.784$	-3 1 :42 rgBT	/O ve rlock 10
420	The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurologica Belgica, 2011, 111, 89-98.	0.5	13
421	Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 741-752.	0.9	13
422	Reproducibility of Brain MRI Lesion Volume Measurements in Multiple Sclerosis Using a Local Thresholding Technique: Effects of Formal Operator Training. European Neurology, 1999, 41, 226-230.	0.6	12
423	Magnetic resonance-based techniques for the study and management of multiple sclerosis. British Medical Bulletin, 2003, 65, 133-144.	2.7	12
424	Toward a definition of structural and functional MRI substrates of fatigue in multiple sclerosis. Journal of the Neurological Sciences, 2007, 263, 1-2.	0.3	12
425	Dirty-Appearing White Matter: A Disregarded Entity in Multiple Sclerosis. American Journal of Neuroradiology, 2010, 31, 390-391.	1.2	12
426	Magnetic Resonance Imaging in Alzheimer's Disease: from Diagnosis to Monitoring Treatment Effect. Current Alzheimer Research, 2012, 9, 1198-1209.	0.7	12
427	Action observation training modifies brain gray matter structure in healthy adult individuals. Brain Imaging and Behavior, 2017, 11, 1343-1352.	1.1	12
428	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. Journal of Neurology, 2018, 265, 896-905.	1.8	12
429	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2019, 25, 968-979.	1.4	12
430	Frontoâ€temporal vulnerability to disconnection in paediatric moderate and severe traumatic brain injury. European Journal of Neurology, 2019, 26, 1183-1190.	1.7	12
431	Dysregulation of multisensory processing stands out from an early stage of migraine: a study in pediatric patients. Journal of Neurology, 2020, 267, 760-769.	1.8	12
432	MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes. Multiple Sclerosis Journal, 2021, 27, 1205-1221.	1.4	12

#	Article	IF	Citations
433	Are machine learning approaches the future to study patients with migraine?. Neurology, 2020, 94, 291-292.	1.5	12
434	Central vein sign and iron rim in multiple sclerosis: ready for clinical use?. Current Opinion in Neurology, 2021, 34, 505-513.	1.8	12
435	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. Journal of the Neurological Sciences, 1998, 159, 94-101.	0.3	11
436	Magnetic resonance imaging techniques to define and monitor tissue damage and repair in multiple sclerosis. Journal of Neurology, 2007, 254, 155-162.	1.8	11
437	Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing–remitting multiple sclerosis. Journal of the Neurological Sciences, 2008, 266, 44-50.	0.3	11
438	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. Multiple Sclerosis Journal, 2011, 17, 319-326.	1.4	11
439	Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis. Journal of Neurology, 2014, 261, 1715-1725.	1.8	11
440	Altered Recruitment of the Attention Network Is Associated with Disability and Cognitive Impairment in Pediatric Patients with Acquired Brain Injury. Neural Plasticity, 2015, 2015, 1-13.	1.0	11
441	Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1402-1409.	1.4	11
442	Clinical predictivity of thalamic sub-regional connectivity in clinically isolated syndrome: a 7-year study. Molecular Psychiatry, 2021, 26, 2163-2174.	4.1	11
443	In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 628-636.	0.9	11
444	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage: Clinical, 2022, 34, 102972.	1.4	11
445	Multiple sclerosis and allied white matter diseases. Neurological Sciences, 2008, 29, 319-322.	0.9	10
446	KIR4.1: another misleading expectation in multiple sclerosis?. Lancet Neurology, The, 2014, 13, 753-755.	4.9	10
447	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. Neurological Sciences, 2018, 39, 1467-1470.	0.9	10
448	Imaging the migrainous brain: the present and the future. Neurological Sciences, 2019, 40, 49-54.	0.9	10
449	Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 139-146.	1.4	10
450	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. Multiple Sclerosis Journal, 2022, 28, 1091-1100.	1.4	10

#	Article	IF	Citations
451	Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence. Neurology, 2021, 97, 989-999.	1.5	10
452	Persistence of congenital mirror movements after hemiplegic stroke. American Journal of Neuroradiology, 2005, 26, 831-4.	1.2	10
453	Increased spatial resolution using a three-dimensional T1-weighted gradient-echo MR sequence results in greater hypointense lesion volumes in multiple sclerosis. American Journal of Neuroradiology, 1998, 19, 235-8.	1.2	10
454	A Comparison Between the Sensitivities of 3â€mm and 5â€mm Thick Serial Brain MRI for Detecting Lesion Volume Changes in Patients with Multiple Sclerosis. Journal of Neuroimaging, 1998, 8, 144-147.	1.0	9
455	Dentate Nucleus T1 Hyperintensity in Multiple Sclerosis: Fig 1 American Journal of Neuroradiology, 2011, 32, E120-E121.	1.2	9
456	New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. Expert Opinion on Medical Diagnostics, 2012, 6, 109-120.	1.6	9
457	Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year) Tj ETQq $1\ 1$	0.784314 1.4	1 rgBT /Overl
458	Estimating Brain Lesion Volume Change in Multiple Sclerosis by Subtraction of Magnetic Resonance Images. Journal of Neuroimaging, 2016, 26, 395-402.	1.0	9
459	Dynamic volumetric changes of hippocampal subfields in clinically isolated syndrome patients: A 2-year MRI study. Multiple Sclerosis Journal, 2019, 25, 1232-1242.	1.4	9
460	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. Neurotherapeutics, 2021, 18, 878-888.	2.1	9
461	Chronic active lesions: a new MRI biomarker to monitor treatment effect in multiple sclerosis?. Expert Review of Neurotherapeutics, 2021, 21, 837-841.	1.4	9
462	Volume of hippocampal subfields and cognitive deficits in neuromyelitis optica spectrum disorders. European Journal of Neurology, 2021, 28, 4167-4177.	1.7	9
463	Demyelination and cortical reorganization: functional MRI data from a case of subacute combined degeneration. NeuroImage, 2003, 18, 558-563.	2.1	8
464	COVID-19 will change MS care forever – No. Multiple Sclerosis Journal, 2020, 26, 1149-1151.	1.4	8
465	Rethinking multiple sclerosis treatment strategies. Lancet Neurology, The, 2020, 19, 281-282.	4.9	8
466	Two-year regional grey and white matter volume changes with natalizumab and fingolimod. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 493-502.	0.9	8
467	Functional and structural MRI correlates of executive functions in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 742-756.	1.4	8
468	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Frontiers in Neurology, 2021, 12, 693333.	1.1	8

#	Article	IF	Citations
469	Activity revealed in MRI of multiple sclerosis without contrast agent A preliminary report. Magnetic Resonance Imaging, 2000, 18, 139-142.	1.0	7
470	Multiple sclerosis: new measures to monitor the disease. Lancet Neurology, The, 2013, 12, 12-13.	4.9	7
471	Linking disability and spinal cord imaging outcomes in MS. Nature Reviews Neurology, 2013, 9, 189-190.	4.9	7
472	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982840.	0.5	7
473	Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. Expert Review of Neurotherapeutics, 2020, 20, 601-618.	1.4	7
474	Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study. Multiple Sclerosis Journal, 2021, 27, 827-840.	1.4	7
475	Corticoâ€subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. European Journal of Neurology, 2021, 28, 2249-2258.	1.7	7
476	Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study. Multiple Sclerosis Journal, 2022, 28, 406-417.	1.4	7
477	Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis. Neurology, 2021, 97, e2007-e2019.	1.5	7
478	Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity. Journal of Neurology, 2022, 269, 1052-1064.	1.8	7
479	A multiparametric brain and cord MR imaging study of a patient with Hirayama disease. American Journal of Neuroradiology, 2006, 27, 2115-7.	1.2	7
480	Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies. Current Neurology and Neuroscience Reports, 2002, 2, 267-276.	2.0	6
481	Headache and migraine. Neurological Sciences, 2008, 29, 336-338.	0.9	6
482	A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. European Radiology, 2009, 19, 2244-2248.	2.3	6
483	The "vegetarian brain― chatting with monkeys and pigs?. Brain Structure and Function, 2013, 218, 1211-1227.	1.2	6
484	Classifying silent progression in relapsing–remitting MS. Nature Reviews Neurology, 2019, 15, 315-316.	4.9	6
485	Neural correlates of visuospatial processing in migraine: does the pain network help?. Molecular Psychiatry, 2021, 26, 6599-6608.	4.1	6
486	Intraobserver and interobserver variability in measuring changes in lesion volume on serial brain MR images in multiple sclerosis. American Journal of Neuroradiology, 1998, 19, 685-7.	1.2	6

#	Article	IF	Citations
487	The association between cognition and motor performance is beyond structural damage in relapsing–remitting multiple sclerosis. Journal of Neurology, 2022, 269, 4213-4221.	1.8	6
488	The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study. Journal of Neurology, 2022, 269, 3841-3857.	1.8	6
489	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability. European Journal of Neurology, 2022, 29, 2036-2046.	1.7	6
490	Lesion load measurements in multiple sclerosis: the effect of incorporating magnetization transfer contrast in a Fast-Flair sequence. Magnetic Resonance Imaging, 1999, 17, 459-461.	1.0	5
491	Evaluation and training of hands and feet movements performed with different strategies: A kinematic study. Clinical Neurology and Neurosurgery, 2011, 113, 218-223.	0.6	5
492	Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations. Journal of Neurology, 2015, 262, 1216-1227.	1.8	5
493	Promoting physical activity to control multiple sclerosis from childhood. Neurology, 2015, 85, 1644-1645.	1.5	5
494	A Semiautomatic Method for Multiple Sclerosis Lesion Segmentation on Dual-Echo MR Imaging: Application in a Multicenter Context. American Journal of Neuroradiology, 2016, 37, 2043-2049.	1.2	5
495	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. Brain Imaging and Behavior, 2017, 11, 1238-1247.	1.1	5
496	Targeting progression in multiple sclerosis â€" an update. Nature Reviews Neurology, 2019, 15, 62-64.	4.9	5
497	Quantitative MRI adds to neuropsychiatric lupus diagnostics. Rheumatology, 2021, 60, 3278-3288.	0.9	5
498	Regional assessment of brain atrophy: a novel approach to achieve a more complete picture of tissue damage associated with central nervous system disorders?. American Journal of Neuroradiology, 2007, 28, 260-1.	1.2	5
499	MRI of Transcallosal White Matter Helps to Predict Motor Impairment in Multiple Sclerosis. Radiology, 2022, 302, 639-649.	3.6	5
500	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. Multiple Sclerosis and Related Disorders, 2022, 61, 103778.	0.9	5
501	Pediatric multiple sclerosis: developments in timely diagnosis and prognostication. Expert Review of Neurotherapeutics, 2022, 22, 393-403.	1.4	5
502	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, , 135245852210881.	1.4	5
503	Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study. Multiple Sclerosis Journal, 2022, 28, 2057-2069.	1.4	5
504	The effect of cross-talk on MRI lesion numbers and volumes in multiple sclerosis using conventional and turbo spin-echo. Multiple Sclerosis Journal, 1998, 4, 471-474.	1.4	4

#	Article	IF	CITATIONS
505	Detecting New Lesion Formation in Multiple Sclerosis: The Relative Contributions of Monthly Dual-Echo and $T < sub > 1 < sub > 0$. He will be a scans of the Relative Contributions of Monthly Dual-Echo and $T < sub > 1 < sub > 0$. He will be a sub of the Relative Contributions of Monthly Dual-Echo and Total Relative	0.6	4
506	Diffusion tensor and magnetization transfer MR imaging of early-onset multiple sclerosis. Neurological Sciences, 2004, 25, s344-s345.	0.9	4
507	The multiple sclerosis mystery: is there a vascular component?. Lancet Neurology, The, 2011, 10, 597-598.	4.9	4
508	Vitamin A: yet another player in multiple sclerosis pathogenesis?. Expert Review of Clinical Immunology, 2013, 9, 113-115.	1.3	4
509	Let's rehabilitate cognitive rehabilitation in multiple sclerosis. Neurology, 2013, 81, 2060-2061.	1.5	4
510	Editorial: Plasticity in Multiple Sclerosis: From Molecular to System Level, from Adaptation to Maladaptation. Frontiers in Neurology, 2015, 6, 265.	1.1	4
511	Simvastatin and cognition in multiple sclerosis. Lancet Neurology, The, 2017, 16, 572-573.	4.9	4
512	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. Multiple Sclerosis and Related Disorders, 2018, 25, 73-76.	0.9	4
513	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. Acta Neurologica Scandinavica, 2018, 138, 447-453.	1.0	4
514	Cortical Lesions on 7-T MRI in Multiple Sclerosis: A Window into Pathogenetic Mechanisms?. Radiology, 2019, 291, 750-751.	3.6	4
515	Extent and characteristics of carotid plaques and brain parenchymal loss in asymptomatic patients with no indication for revascularization. IJC Heart and Vasculature, 2020, 30, 100619.	0.6	4
516	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	1.8	4
517	Resting-State fMRI in Multiple Sclerosis. , 2020, , 335-353.		4
518	A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 1268-72.	1.2	4
519	Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis. Journal of Neurology, 2022, 269, 4729-4741.	1.8	4
520	Monitoring long-term treatments in multiple sclerosis. Nature Reviews Neurology, 2010, 6, 421-422.	4.9	3
521	Clinical Applications of the Functional Connectome. Neuromethods, 2016, , 893-903.	0.2	3
522	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. NeuroImage: Clinical, 2021, 30, 102659.	1.4	3

#	Article	IF	CITATIONS
523	Improved Assessment of Longitudinal Spinal Cord Atrophy in Multiple Sclerosis Using a <scp>Registrationâ€Based</scp> Approach: Relevance for Clinical Studies. Journal of Magnetic Resonance Imaging, 2022, 55, 1559-1568.	1.9	3
524	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. Multiple Sclerosis Journal, 2022, 28, 885-899.	1.4	3
525	Siponimod for Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, 91-92.	1.5	3
526	Divergent time-varying connectivity of thalamic sub-regions characterizes clinical phenotypes and cognitive status in multiple sclerosis. Molecular Psychiatry, 2022, 27, 1765-1773.	4.1	3
527	Mapping brain structure and function in professional fencers: AÂmodel to study training effects on central nervous system plasticity. Human Brain Mapping, 2022, 43, 3375-3385.	1.9	3
528	Resting state effective connectivity abnormalities of the Papez circuit and cognitive performance in multiple sclerosis. Molecular Psychiatry, 0, , .	4.1	3
529	Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. Neurotherapeutics, 2022, 19, 1216-1228.	2.1	3
530	Brain adaptive changes following tissue damage in PPMS: a multiparametric study using F-MRI, MTI and DTI. NeuroImage, 2001, 13, 789.	2.1	2
531	Brain Plasticity in Multiple Sclerosis. European Neurology, 2004, 51, 189-190.	0.6	2
532	Toward a better understanding of cerebral plasticity in multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 1-2.	0.3	2
533	Application of fMRI to the study of multiple sclerosis: an update. Future Neurology, 2008, 3, 141-151.	0.9	2
534	The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately – No. Multiple Sclerosis Journal, 2012, 18, 557-558.	1.4	2
535	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. Journal of the Neurological Sciences, 2016, 361, 184-186.	0.3	2
536	The Role of DTI in Multiple Sclerosis and Other Demyelinating Conditions. , 2016, , 331-341.		2
537	Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 373-373.	0.9	2
538	PET is necessary to make the next step forward in understanding MS pathophysiology – No. Multiple Sclerosis Journal, 2019, 25, 1088-1090.	1.4	2
539	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. Neurotherapeutics, 2021, 18, 1623-1636.	2.1	2
540	Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients. European Journal of Neurology, 2021, 28, 2513-2522.	1.7	2

#	Article	IF	Citations
541	Application of deep-learning to the seronegative side of the NMO spectrum. Journal of Neurology, 2022, 269, 1546-1556.	1.8	2
542	Functional magnetic resonance imaging and multiple sclerosis. Future Neurology, 2006, 1 , 67-76.	0.9	2
543	Current and future applications of artificial intelligence in multiple sclerosis. , 2022, , 107-144.		2
544	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 382-384.	1.4	1
545	Measures of magnetization transfer. , 0, , 112-127.		1
546	Brain structural and functional abnormalities in Fahr's disease : a report of two cases. Journal of Neurology, 2013, 260, 1927-1930.	1.8	1
547	A Semi-automatic Method for Segmentation of Multiple Sclerosis Lesions on Dual-Echo Magnetic Resonance Images. Lecture Notes in Computer Science, 2016, , 80-90.	1.0	1
548	fMRI of Pain. Neuromethods, 2016, , 495-521.	0.2	1
549	fMRI of the Sensorimotor System. Neuromethods, 2016, , 523-543.	0.2	1
550	Dynamic Functional Connectivity For The Classification Of Multiple Sclerosis Phenotype: A Hidden Markov Model Approach., 2021,,.		1
551	Multiple sclerosis and related disorders. , 2015, , 168-184.		1
552	MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2022, , jnnp-2022-328956.	0.9	1
553	Diffusion and perfusion MRI in inflammation and demyelination. , 0, , 488-500.		0
554	<i>Reply:</i> . American Journal of Neuroradiology, 2010, 31, E46-E46.	1.2	0
555	Assessing lesion morphology in MS: Why does this matter?. Journal of the Neurological Sciences, 2010, 290, 194-195.	0.3	0
556	Acute, multifocal neurologicalsymptoms., 0,, 209-227.		0
557	Demyelinating Diseases. , 2015, , 895-905.		0
558	Application of fMRI to Multiple Sclerosis and Other White Matter Disorders. Neuromethods, 2016, , 609-637.	0.2	0

#	Article	IF	Citations
559	fMRI in Psychiatric Disorders. Neuromethods, 2016, , 657-697.	0.2	O
560	Surrogate Markers in Multiple Sclerosis. , 2016, , 163-187.		0
561	Preface. Acta Neurologica Scandinavica, 2016, 134, 3-3.	1.0	0
562	Characteristics of carotid atherosclerosis and brain white matter hyperintensities in asymptomatic patients with intermediate stenosis. Atherosclerosis, 2017, 263, e57.	0.4	0
563	Cognitive Processes Underlying Vegetarianism as Assessed by Brain Imaging. , 2017, , 71-91.		O
564	Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study. Neurology, 2019, 92, 587.2-588.	1.5	0
565	Editorial for "Utility of Advanced <scp>DWI</scp> in the Detection of Spinal Cord Microstructural Alterations and Assessment of Neurologic Function in Cervical Spondylotic Myelopathy Patients― Journal of Magnetic Resonance Imaging, 2022, 55, 941-942.	1.9	0
566	Encoding Brain Networks Through Geodesic Clustering of Functional Connectivity for Multiple Sclerosis Classification., 2021, , .		0
567	Functional Magnetic Resonance Imaging. , 2002, , 113-124.		O
568	Diffusion-Weighted MRI., 2003,, 33-45.		0
569	Functional MRI., 2003, , 83-97.		0
570	The Grey Matter Component of MS Pathology: Magnetization Transfer and Diffusion-Weighted Imaging. , 2004, , 121-127.		0
571	Functional MRI in Multiple Sclerosis. , 2004, , 145-155.		0
572	MRI-Clinical Correlations in Multiple Sclerosis: Implications for Our Understanding of Neuronal Changes., 2005,, 215-225.		0
573	Application of fMRI to Multiple Sclerosis and Other White Matter Disorders. Neuromethods, 2009, , 573-596.	0.2	0
574	fMRI of the Sensorimotor System. Neuromethods, 2009, , 493-511.	0.2	0
575	Diffusion Tensor MRI in Multiple Sclerosis. , 2010, , 564-571.		O
576	Diffusion Tensor Imaging Abnormalities in Migraine. , 2012, , 188-194.		0

#	Article	IF	CITATIONS
577	Imaging of Migraine and Vestibular Migraine. , 2014, , 193-209.		O
578	Spinal cord diseases. , 2015, , 323-334.		O
579	High-Field-Strength MRI (3.0 T or More) in White Matter Diseases. , 2017, , 223-237.		O
580	Neuromyelitis Optica Spectrum Disorders. , 2020, , 67-94.		0
581	Pediatric Multiple Sclerosis. , 2020, , 37-66.		O
582	Functional MRI. , 2007, , 85-104.		0
583	Multiple Sclerosis: Other MR Techniques. , 2005, , 225-240.		O
584	Spinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp> . Annals of Neurology, 2022, 91, 734-735.	2.8	0
585	Editorial for "Amide Proton Transfer <scp>MRI</scp> Could Be Used to Evaluate the Pathophysiological Status of White Matter Hyperintensitiesâ€. Journal of Magnetic Resonance Imaging, 2022, 56, 310-311.	1.9	O
586	Magnetic resonance imaging to assess gray matter damage in multiple sclerosis., 0,, 86-92.		0
587	Application of functional magnetic resonance imaging in multiple sclerosis., 0,, 93-102.		O
588	Functional magnetic resonance imaging monitoring of the rapeutic interventions in multiple sclerosis. , 0, , 120-126.		0
589	Aging Brain. , 2008, , 52-55.		0